US stocks stumble as Moderna sinks on report questioning trial results


A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against Covid-19 - Reuters

NEW YORK (Reuters): The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out modest gains on the benchmark index in the last hour of trading.

Major averages fell to session lows in the wake of a report from STAT News that questioned the validity of the results of Moderna's vaccine trial, which the company had announced Monday.

Moderna Inc shares plunged after the report, and closed down 10.41%.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Moderna , clinical trials , Wall Street

   

Next In Business News

No one escapes closing costs
AI revolution in property industry
Simplifying pre-approved home loans
Ringgit likely to trade higher next week
GREEN GROWTH PLAN
99 Speed Mart 3Q numbers driven by outlet expansion
Short-term pain, long-term gain
Tailwinds in private aircraft servicing
5G saga transmits mixed signals
BiiB makes big strides in running

Others Also Read